IDO1 and melanoma: However, even if the results of phase I and II clinical trials launched to test the efficiency of IDO1 inhibitors for the treatment of melanoma were encouraging106, the development of the drugs was stopped due to the lack of the efficiency of their combination with anti-PD1 for melanoma treatment107.